Eugene Sun, MD

Senior Medical Advisor, BARDA

Dr. Eugene Sun is currently appointed as a Senior Medical Advisor to BARDA since November 2018.  He has served as a board director of Novan, Inc. since February, 2018.  He served as the Chief Executive Officer for Melinta Therapeutics from 2015 to 2017 and as its Executive Vice President from 2013 to 2015.  Prior to joining Melinta, Dr. Sun held senior positions at Abbott Laboratories, most recently as Corporate Vice President, Global Pharmaceutical Clinical Development, responsible for clinical development, medical affairs and clinical operations across the pharmaceutical portfolio. During his 17-year tenure at Abbott, Dr. Sun led the development and worldwide regulatory approval of the landmark human immunodeficiency virus (HIV) protease inhibitor Kaletra® and oversaw the development and approval of multiple indications for Humira®. From 2001 to 2007, Dr. Sun served on the U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee, a panel of independent infectious disease experts. After earning an undergraduate degree from Harvard University and a medical degree from New York University School of Medicine, Dr. Sun completed an internship and residency in internal medicine and a fellowship in infectious diseases at the University of California, San Francisco. During his fellowship, Dr. Sun received a National Research Service Award and a Physician Scientist Award from the National Institutes of Health.